|
The Scientist: NewsBlog:
NCI tackles trial enrollment
Posted by Edyta Zielinska [Entry posted at 22nd July 2009 05:03 PM GMT]
Rate this article
Accessing global population is key by John Lewis [Comment posted 2009-07-23 09:22:17] This is a very good initiative from NCI but to truly accelerate patient recruitment and the drug development process we must look beyond the borders of the United States and access the global population. Cancer is not a U.S-only disease. Research released this week by the Association of Clinical Research Organizations (ACRO) shows that the enrollment time for cancer trials can be reduced by two-thirds - from nearly six years to less than two years - by conducting the research globally. This means, potentially, that a new treatment can be made available four years sooner, saving countless lives. The report also found that safety, ethics and quality in global trials are at the same levels as U.S. trials. The full report can be accessed at www.acrohealth.org/globalization. Thank you. Genotype pools needed for drug research by Cheryl Soehl [Comment posted 2009-07-22 14:29:06] Perhaps more important than research by gender is clinical trials by genetic phenotype. When drugs are developed based on a one size fits all model, the minority of people who may be adversely affected are written off as not statistically significant; however, if 100% of a particular genetic minority is affected, the consequences could be disastrous for that group.
How about establishing a database of possible subjects classified by phenotype for testing drug safety? Comment on this blog |